In a report released on February 28, Llelleythan Tan from UOB Kay Hian maintained a Buy rating on Raffles Medical Group (RAFLF – Research Report), with a price target of S$1.85. The company’s shares closed last Wednesday at $1.07.
According to TipRanks, Tan is an analyst with an average return of -6.8% and a 28.57% success rate.
Currently, the analyst consensus on Raffles Medical Group is a Moderate Buy with an average price target of $1.28, implying a 19.63% upside from current levels. In a report released on February 28, CLSA also maintained a Buy rating on the stock with a S$1.92 price target.
See the top stocks recommended by analysts >>
RAFLF market cap is currently $1.94B and has a P/E ratio of 19.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Raffles Medical Group Ltd. is an investment holding company, which engages in the operation of medical clinics and other general medical services. It operates through the following segments: Healthcare Services, Hospital Services, and Investment Holdings. The Healthcare Services segment includes the management of medical clinics and other general medical services, provision of health insurance, trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management and consultancy services. The Hospital Services segment provides specialized medical services and operates hospital and business of medical laboratory and imaging center. The Investment Holdings segment refers to the investment properties. The company was founded by Choon Yong Loo and Alfred Loh in 1976 and is headquartered in Singapore.
Read More on RAFLF:
